Skip to main content
Log in

Pharmacological and biochemical studies on protective effects of mangiferin and its interaction with nitric oxide (NO) modulators in adjuvant-induced changes in arthritic parameters, inflammatory, and oxidative biomarkers in rats

  • Original Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Current study was designed to evaluate protective effect of mangiferin and its interaction with low dose of nitric oxide (NO) modulators in complete Freund’s adjuvant (CFA) inoculated rats. Male wistar rats (200–300 g, n = 8 per group) were used in the study. On day ‘‘0’’ of study arthritis was induced in rats by injecting 0.2 ml CFA in sub-planter region of right hind paw of animals. Treatment with methotrexate (5 mg/kg), mangiferin (10–30 mg/kg) alone and in combination with NO modulators was given (i.p.) from days 14 to 28. After 28 days, blood and joint synovial fluid was collected for biochemical analysis and rat paws were excised to estimate MDA and SOD in tissue (paw) homogenates. CFA inoculation significantly increases (1) arthritic index, (2) ankle diameter, (3) paw volume, and (4) serum TNF-α, IL-6, IL-1β, and synovial TNF-α levels (p < 0.001). The serum Th1 (IFN-γ) and Th2 (IL-4) cytokine levels, MDA levels in rat paw tissue homogenates and serum NF-κB levels were also found significantly increased. Significant decrease in serum IL-10 levels and SOD activity was found after CFA inoculation. These CFA-induced arthritic changes, cytokine profile, and oxidative stress markers were significantly reversed by mangiferin (10–30 mg/kg) treatment alone and in combination with l-arginine and l-NAME nitric oxide modulators (p < 0.05). Treatment with methotrexate (5 mg/kg) also significantly reversed these adjuvant changes (p < 0.05). However, effect of methotrexate was less marked as compared to mangiferin (30 mg/kg) alone and in combination with l-NAME (10 mg/kg), but was comparable or slightly better than mangiferin (10 and 20 mg/kg). Thus, on the basis of our findings, we can suggest that interaction of mangiferin with nitric oxide modulators may have therapeutic value for chronic inflammatory disease such as RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

CFA:

Complete Freund’s adjuvant

TNF-α:

Tumor necrosis factor alpha

IL:

Interleukin

NEMO:

NF-κB essential modulator

L-NAME:

Nω-nitro-arginine methyl ester hydrochloride

TRAF:

TNF-receptor-associated factor

TRADD:

TNF-receptor-type 1-associated death domain

IFN:

Interferon

IKK:

Inhibitory kappa kinase

References

Download references

Acknowledgements

Authors would like to thank Professor R. K. Dixit, Department of Pharmacology and Therapeutics, KGMU, Lucknow for his expert suggestions and English editing. Authors have not received any kind of assistance and have no relation with Sigma-Aldrich chemical Co. USA from which mangiferin was purchased.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rishi Pal.

Ethics declarations

Conflict of interest

Authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pal, R., Chaudhary, M.J., Tiwari, P.C. et al. Pharmacological and biochemical studies on protective effects of mangiferin and its interaction with nitric oxide (NO) modulators in adjuvant-induced changes in arthritic parameters, inflammatory, and oxidative biomarkers in rats. Inflammopharmacol 27, 291–299 (2019). https://doi.org/10.1007/s10787-018-0507-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-018-0507-8

Keywords

Navigation